Mereo BioPharma(MREO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 London, August 13, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage ...